Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results   

BOSTON, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced its financial results for the quarter ended September 30, 2017. The company also reviewed its progress with Auryxia, upcoming milestones, and withdrew its 2017 financial guidance.